Author
@FiercePharma FiercePharma
Pharma trade outlet relaying FDA, deal, and exec-move newsflow in real time
Institutional pharma/biopharma journalism: breaks and relays
trader score
+1.39
hit rate
69%
mean α
+0.71%
signals 14d
14
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 13 scored bets: 69% hit rate, +0.71% mean alpha, trader score +1.39. Their last-14d mentions, direction-adjusted, have moved +1.8% since posting (mean over 7 mentions with price data).
Recent signals14receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-07-01 | BBIO | @FiercePharma | +0.20 | BridgeBio secured $1B to support launches; analyst says other plans possible. | +3.6% | tweet ↗ |
| 2026-07-01 | HLN | @FiercePharma | +0.25 | Haleon taps Microsoft to incorporate AI across operations. | · | tweet ↗ |
| 2026-06-30 | AMGN | @FiercePharma | -0.25 | Journal retraction complicates Amgen defense effort. | +3.3% | tweet ↗ |
| 2026-06-30 | ONC | @FiercePharma | +0.45 | BeOne's Brukinsa hits goal in confirmatory trial. | · | tweet ↗ |
| 2026-06-30 | UNCY | @FiercePharma | -0.50 | Unicycive turned away by FDA again over plant shortfalls. | · | tweet ↗ |
| 2026-06-30 | ABBV | @FiercePharma | +0.35 | Positive phase 3 combination trial renews confidence for Epkinly. | +3.7% | tweet ↗ |
| 2026-06-30 | GMAB | @FiercePharma | +0.35 | Positive phase 3 combination trial renews confidence for Epkinly. | · | tweet ↗ |
| 2026-06-30 | FUJIY | @FiercePharma | +0.20 | FDA selects Lilly, Regeneron, Fujifilm and others for PreCheck pilot. | · | tweet ↗ |
| 2026-06-30 | LLY | @FiercePharma | +0.20 | FDA selects Lilly, Regeneron, Fujifilm and others for PreCheck pilot. | +1.2% | tweet ↗ |
| 2026-06-30 | REGN | @FiercePharma | +0.20 | FDA selects Lilly, Regeneron, Fujifilm and others for PreCheck pilot. | +4.9% | tweet ↗ |
| 2026-06-30 | AMGN | @FiercePharma | -0.15 | Viridian secured FDA approval for Lumvoa, creating competition for Amgen Tepezza. | +3.3% | tweet ↗ |
| 2026-06-30 | VRDN | @FiercePharma | +0.50 | Viridian secured FDA approval for Lumvoa, creating competition for Amgen Tepezza. | +5.6% | tweet ↗ |
| 2026-06-24 | · | @FiercePharma | · | Nature Medicine pulled a controversial paper tying lung cancer survival to PD-1 treatment timing. | · | tweet ↗ |
| 2026-06-22 | · | @FiercePharma | · | World's first solid tumor approval for CAR-T therapy arrives in China. | · | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.